Previous Article | Next Article ![]()
Journal of Clinical Microbiology, October 2002, p. 3631-3634, Vol. 40, No. 10
0095-1137/02/$04.00+0 DOI: 10.1128/JCM.40.10.3631-3634.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Departments of Medicine,1 Epidemiology,2 Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina3
Received 24 April 2002/ Returned for modification 19 June 2002/ Accepted 8 July 2002
|
|
|---|
|
|
|---|
Previous attempts to quantify C. trachomatis infection employed quantitative culture. Most assays rely on an indirect estimation of an infected individual's organism burden by a count of the number of chlamydial inclusion-forming units in a monolayer of tissue culture cells. These studies have been limited by the relative insensitivity of culture (9), variability of infectivity of host cells under different culture conditions (7, 11), and an inability to adequately quantify a broad range of organism concentration.
Despite these limitations, several studies suggest that some broad epidemiological factors are related to the quantity of C. trachomatis present (1, 2, 4, 6, 10). While younger age, Caucasian race, oral contraception use, low secretory immunoglobulin secretion and cervical ectopy appear to be related to higher organism burdens, the associations of Chlamydia quantities with gender and concurrent infection with Neisseria gonorrhoeae are variable. A recent study demonstrated a relationship between chlamydial inclusion-forming units and clinical manifestations of disease, such as the degree of cervicitis or pelvic inflammatory disease in women and urethritis in men (5). More sensitive detection and quantification methods are needed to guide public health interventions and answer key epidemiological questions about the transmission and pathogenesis of this infection.
Recently, Thomas et al. (14) correlated higher values from ligase chain reactions (LCR) in clinical samples with higher chlamydial burdens observed by direct fluorescent antibody testing. However, C. trachomatis was not precisely quantified in clinical samples. In the present study, we modified the standard LCR protocol to provide quantitative chlamydial data from clinical urine samples over a broad range of organism concentrations. The assay was used to quantify C. trachomatis in urine from infected women.
|
|
|---|
Preparation of C. trachomatis stock. C. trachomatis was cultivated as previously described with slight modification (3). Briefly, McCoy cells (ATCC 1696) were grown to near confluence in Dulbecco's modified medium supplemented with 5% fetal bovine serum, 25 mM HEPES, 2 mM L-glutamine, and gentamicin (10 µg/ml) at 37°C in 5% CO2. McCoy cell division was arrested with cycloheximide as described previously (3). C. trachomatis serovar E elementary bodies (EB) (generously provided by Priscilla B. Wyrick, East Tennessee State University) were added and incubated for 48 to 72 h at 35°C. The contents of several culture flasks were pooled, sonicated for 5 min, and centrifuged at 500 x g for 10 min at 4°C to remove cellular debris. The supernatant was centrifuged at 10,000 x g for 30 min at 4°C; the resulting pellet was resuspended in buffer containing sucrose, phosphate, and glutamate (2-SPG). EB were isolated from this crude C. trachomatis preparation by purification over a Renografin gradient. Purified EB were suspended in 2-SPG, aliquoted, and stored at -80°C.
Quantification of C. trachomatis stock solution. Purified EB were thawed at 37°C and sonicated on ice for 5 min. The concentration of C. trachomatis EB was determined by direct microscopic count using a fluorescein-labeled monoclonal antibody as previously described (8). Briefly, 10 µl of a 1:4 dilution of EB stock solution was placed into 6-mm-diameter wells on a Teflon-coated slide (catalog no. 63424-06; Electron Microscopy Sciences), air dried, and fixed with 70% ethanol-30% acetone for 10 min. Wells were incubated with 15 µl of fluorescein isothiocyanate-labeled antichlamydia antibody (chlamydia confirmation kit [catalog no. 8H0194]; Wompole Labs) for 30 min at 37°C; slides were rinsed and allowed to air dry in the dark.
Immediately after staining, slides were viewed using a Zeiss LSM210 confocal laser scanning microscope in epifluorescence mode with a magnification of x1,000. Nine fields were counted for each well; seven individual wells on four independent slides were examined. The area per high-power field (hpf) was determined using a stage micrometer. The mean number of organisms per hpf was determined for each well and averaged for seven wells. The stock concentration of EB per milliliter was determined using the following formula: (average no. of EB per hpf) x (area of individual well) x (reciprocal dilution of stock) x 1,000/(area per hpf) x (volume of sample [in microliters]).
Preparation of quantitative standards. For quantitative LCR (qLCR), three overlapping series of twofold dilutions of C. trachomatis stock solution were prepared in pooled urine from uninfected volunteers. Several diluents were tested by using the standard LCR urine sample preparation procedure (Abbott LCx probe system); pooled urine resulted in higher rates by LCR than did 2-SPG or phosphate-buffered saline. Low-range standards contained 3.2 x 101 to 1.0 x 103 EB/ml, medium-range standards contained 5.1 x 102 to 3.3 x 104 EB/ml, and high-range standards contained 1.6 x 104 to 1.0 x 107 EB/ml. When necessary, a medium-low-range standard with 1.3 x 102 to 4.1 x 103 EB/ml or a high-medium-range standard containing 4.1 x 103 to 1.0 x 103 EB/ml was used. C. trachomatis stock solutions and LCR preparations that were frozen and thawed up to 20 times prior to qLCR testing showed no significant decrease in LCR rate. To maximize uniformity of individual test runs, an initial stock was quantified microscopically, aliquoted into multiple-use vials, and frozen at -80°C. Dilutions were made from a freshly thawed stock solution and prepared according to the LCR urine protocol. For each qLCR run, an appropriate standard dilution series was amplified with clinical specimens.
qLCR.
Clinical urine specimens were screened using the Abbott LCx probe system according to the manufacturer's instructions. For qLCR, positive urine specimens were prepared according to the standard LCR protocol and amplified alongside a medium-standard series for 30 cycles of the otherwise-standard thermocycler profile. The log2 of the LCR rate was plotted against the concentration of each standard, and linear regression was used to generate the equation of the line. A valid qLCR run was defined as one for which there was an increasing LCR sample rate for each standard in the series and the R2 of the regression line was
0.900. Chlamydia concentrations in clinical specimens were calculated from the equation of the standard line.
To verify the reproducibility of LCR with altered cycle numbers, five preparations were made from a clinical urine sample that tested positive for C. trachomatis by the standard LCR. Each preparation was amplified using 30 cycles, and one preparation was tested five different times. There was minimal variation between preparations and between tests with the same preparation.
Samples that fell outside the linear range of the medium-standard series were retested using the low-standard series at 35 amplification cycles or the high-standard series at 25 cycles, as appropriate. In rare instances, LCR sample rates were not squarely within the medium-standard or the subsequent series. These samples were analyzed with an intermediate series, 33 cycles for the medium-low-range standard series or 28 cycles for the high-medium-range standard series.
Statistical analysis. Descriptive statistics and linear and polynomial regression were performed using SigmaStat software (version 2.03; SPSS, Inc.).
|
|
|---|
![]() View larger version (21K): [in a new window] |
FIG. 1. Linear regression of representative qLCR standard curves. Low-range standards were amplified through 35 cycles (R2 = 0.95), medium-range standards were amplified through 30 cycles (R2 = 0.99), and high-range standards were amplified through 25 cycles (R2 = 0.97) as described in Materials and Methods.
|
2 was 140 EB/ml of urine. This demonstrates that the degree of amplification provided by the qualitative test shifted the values for the higher concentrations to the asymptotic portion of the sigmoid curve. The higher correlation coefficient of the qLCR method suggests that the quantitative standards provided a better estimate for quantification than the internal standards of the qualitative LCR assay.
![]() View larger version (24K): [in a new window] |
FIG. 2. Comparison of standard LCR S/CO values and qLCR results from clinical urine specimens from Malagasy women. The solid line is the second-order-regression line (R = 0.615); dotted lines represent the 95% confidence intervals of the regression line.
|
![]() View larger version (29K): [in a new window] |
FIG. 3. Histogram of the distribution of qLCR values obtained with clinical urine specimens from Malagasy women. The numbers above the bars indicate the number of specimens with values in the range of concentrations indicated on the x axis.
|
|
|
|---|
Despite these advantages, qLCR is not without limitations. The most significant may be the use of urine to assess genital organism burden. Specimen volume can influence the amount of chlamydia recovered in first-void urine. The use of urine as a surrogate for cervical or urethral swabs has become acceptable for diagnosis but is so far untested for quantification. To correlate infectivity with quantitative C. trachomatis testing, cervical or vaginal vault sampling may provide a better assessment for women. For men, infectivity is likely related to the chlamydia concentration in semen; however, inhibitors of the LCR are a potential complication. Additional studies are required to quantify C. trachomatis in semen as well as to correlate results of qLCR using urine and those of qLCR using genital specimens from men and women.
Variation in copy number for the plasmid containing the LCR target is also a potential source of error in this assay. C. trachomatis strains maintain 7 to 10 copies of this plasmid (12, 13); this range could introduce less than a twofold error in the measured concentration. In addition, a clinical isolate lacking this plasmid entirely has been reported (13). The extent to which similar isolates might occur would obviously impact the utility of both standard LCR and qLCR with the current primers.
Studies to quantify C. trachomatis in partners of infected persons may provide evidence of the importance of organism burden in transmission. The amount of chlamydia present in symptomatic versus asymptomatic women and in prevalent versus incident disease could have great public health importance. Moreover, determining the relationship between chlamydial concentration and clinical presentation will shed light on the immunology of this infection. This could lead to a better understanding of asymptomatic disease and its role in perpetuating chlamydial infections in populations; the development of significant morbidity, such as pelvic inflammatory disease, chronic abdominal pain, and infertility; and the increased risk of transmission of human immunodeficiency virus from coinfected persons.
Given the limited resources available for the prevention and control of chlamydial infection, a better understanding of the epidemiology of the transmission cycle is essential to develop better strategies to decrease the burden of this infection. qLCR should be a useful tool to assess these strategies and to pursue cost-effective interventions.
We thank Jason Gratz and Stephen Knight for technical assistance; Kristi McClamrock, Bill Miller, Priscilla Wyrick, Jane Raulston, and Helen Lee for helpful discussions; and Kathleen Van Damme and the clinicians, technicians, and subjects in Madagascar for making this study possible.
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»